 | • レポートコード：MRC2312MG00363 • 出版社/出版日：Market Monitor Global / 2023年12月 • レポート形態：英文、PDF、107ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医療 |
| Single User | ￥481,000 (USD3,250) | ▷ お問い合わせ |
| Enterprise User | ￥721,500 (USD4,875) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査レポートは次の情報を含め、世界のペプチド&オリゴヌクレオチドCDMO市場規模と予測を収録しています。・世界のペプチド&オリゴヌクレオチドCDMO市場：売上、2018年-2023年、2024年-2029年 ・世界のペプチド&オリゴヌクレオチドCDMO市場：販売量、2018年-2023年、2024年-2029年 ・世界のトップ5企業、2022年 世界のペプチド&オリゴヌクレオチドCDMO市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「ペプチドCDMO」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。 ペプチド&オリゴヌクレオチドCDMOのグローバル主要企業は、Lonza Group Ltd.、 Thermo Fisher Scientific Inc.、 Merck KGaA、 Catalent, Inc.、 Genscript Biotech Corporation、 Polypeptide Group、 Bachem Holding AG、 Wuxi Apptec Co., Ltd.、 Ajinomoto Co., Inc.、 Rentschler Biopharma SE、 Corden Pharma GmbH、 Senn Chemicals AG、 Almac Group、 Lonza Custom Manufacturing、 Creative Peptides、 Swiss Customized Synthesis、 Syngene、 Eurogentecなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。 MARKET MONITOR GLOBAL（MMG）は、ペプチド&オリゴヌクレオチドCDMOのメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別市場分析】 世界のペプチド&オリゴヌクレオチドCDMO市場：タイプ別、2018年-2023年、2024年-2029年 世界のペプチド&オリゴヌクレオチドCDMO市場：タイプ別市場シェア、2022年 ・ペプチドCDMO、オリゴヌクレオチドCDMO 世界のペプチド&オリゴヌクレオチドCDMO市場：用途別、2018年-2023年、2024年-2029年 世界のペプチド&オリゴヌクレオチドCDMO市場：用途別市場シェア、2022年 ・製薬＆バイオ企業、研究機関、その他 世界のペプチド&オリゴヌクレオチドCDMO市場：地域・国別、2018年-2023年、2024年-2029年 世界のペプチド&オリゴヌクレオチドCDMO市場：地域別市場シェア、2022年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競合分析】 また、当レポートは主要な市場参加者の分析を提供します。 ・主要企業におけるペプチド&オリゴヌクレオチドCDMOのグローバル売上、2018年-2023年 ・主要企業におけるペプチド&オリゴヌクレオチドCDMOのグローバル売上シェア、2022年 ・主要企業におけるペプチド&オリゴヌクレオチドCDMOのグローバル販売量、2018年-2023年 ・主要企業におけるペプチド&オリゴヌクレオチドCDMOのグローバル販売量シェア、2022年 さらに、当レポートは主要企業のプロファイルを提示します。 Lonza Group Ltd.、 Thermo Fisher Scientific Inc.、 Merck KGaA、 Catalent, Inc.、 Genscript Biotech Corporation、 Polypeptide Group、 Bachem Holding AG、 Wuxi Apptec Co., Ltd.、 Ajinomoto Co., Inc.、 Rentschler Biopharma SE、 Corden Pharma GmbH、 Senn Chemicals AG、 Almac Group、 Lonza Custom Manufacturing、 Creative Peptides、 Swiss Customized Synthesis、 Syngene、 Eurogentec ************************************************************* ・調査・分析レポートの概要 ペプチド&オリゴヌクレオチドCDMO市場の定義 市場セグメント 世界のペプチド&オリゴヌクレオチドCDMO市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界のペプチド&オリゴヌクレオチドCDMO市場規模 世界のペプチド&オリゴヌクレオチドCDMO市場規模：2022年 VS 2029年 世界のペプチド&オリゴヌクレオチドCDMO市場規模と予測 2018年-2029年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでのペプチド&オリゴヌクレオチドCDMOの売上 グローバルトップ3およびトップ5企業、2022年売上ベース グローバル企業のペプチド&オリゴヌクレオチドCDMO製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：ペプチドCDMO、オリゴヌクレオチドCDMO ペプチド&オリゴヌクレオチドCDMOのタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：製薬＆バイオ企業、研究機関、その他 ペプチド&オリゴヌクレオチドCDMOの用途別グローバル売上・予測 ・地域別市場分析 地域別ペプチド&オリゴヌクレオチドCDMO市場規模 2022年と2029年 地域別ペプチド&オリゴヌクレオチドCDMO売上・予測 北米市場：アメリカ、カナダ、メキシコ ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア アジア市場：中国、日本、韓国、東南アジア、インド 南米市場：ブラジル、アルゼンチン 中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE ・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど） Lonza Group Ltd.、 Thermo Fisher Scientific Inc.、 Merck KGaA、 Catalent, Inc.、 Genscript Biotech Corporation、 Polypeptide Group、 Bachem Holding AG、 Wuxi Apptec Co., Ltd.、 Ajinomoto Co., Inc.、 Rentschler Biopharma SE、 Corden Pharma GmbH、 Senn Chemicals AG、 Almac Group、 Lonza Custom Manufacturing、 Creative Peptides、 Swiss Customized Synthesis、 Syngene、 Eurogentec ... |
This research report provides a comprehensive analysis of the Peptide and Oligonucleotide CDMO market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Peptide and Oligonucleotide CDMO market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Peptide and Oligonucleotide CDMO, challenges faced by the industry, and potential opportunities for market players.
The global Peptide and Oligonucleotide CDMO market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Peptide and Oligonucleotide CDMO market presents opportunities for various stakeholders, including Pharmaceutical and Biotechnology Companies, Research Institutes. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Peptide and Oligonucleotide CDMO market. Additionally, the growing consumer demand present avenues for market expansion.
The global Peptide and Oligonucleotide CDMO market was valued at US$ 1509.1 million in 2022 and is projected to reach US$ 3026.6 million by 2029, at a CAGR of 10.5% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Key Features:
The research report on the Peptide and Oligonucleotide CDMO market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Peptide and Oligonucleotide CDMO market.
Market Overview: The report provides a comprehensive overview of the Peptide and Oligonucleotide CDMO market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Peptide CDMO, Oligonucleotide CDMO), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Peptide and Oligonucleotide CDMO market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Peptide and Oligonucleotide CDMO market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Peptide and Oligonucleotide CDMO market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Peptide and Oligonucleotide CDMO market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Peptide and Oligonucleotide CDMO market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Peptide and Oligonucleotide CDMO market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Peptide and Oligonucleotide CDMO, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Peptide and Oligonucleotide CDMO market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Peptide and Oligonucleotide CDMO market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Peptide CDMO
Oligonucleotide CDMO
Market segment by Application
Pharmaceutical and Biotechnology Companies
Research Institutes
Others
Global Peptide and Oligonucleotide CDMO Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
Lonza Group Ltd.
Thermo Fisher Scientific Inc.
Merck KGaA
Catalent, Inc.
Genscript Biotech Corporation
Polypeptide Group
Bachem Holding AG
Wuxi Apptec Co., Ltd.
Ajinomoto Co., Inc.
Rentschler Biopharma SE
Corden Pharma GmbH
Senn Chemicals AG
Almac Group
Lonza Custom Manufacturing
Creative Peptides
Swiss Customized Synthesis
Syngene
Eurogentec
Outline of Major Chapters:
Chapter 1: Introduces the definition of Peptide and Oligonucleotide CDMO, market overview.
Chapter 2: Global Peptide and Oligonucleotide CDMO market size in revenue.
Chapter 3: Detailed analysis of Peptide and Oligonucleotide CDMO company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Peptide and Oligonucleotide CDMO in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
1 Introduction to Research & Analysis Reports
1.1 Peptide and Oligonucleotide CDMO Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Peptide and Oligonucleotide CDMO Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Peptide and Oligonucleotide CDMO Overall Market Size
2.1 Global Peptide and Oligonucleotide CDMO Market Size: 2022 VS 2029
2.2 Global Peptide and Oligonucleotide CDMO Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Peptide and Oligonucleotide CDMO Players in Global Market
3.2 Top Global Peptide and Oligonucleotide CDMO Companies Ranked by Revenue
3.3 Global Peptide and Oligonucleotide CDMO Revenue by Companies
3.4 Top 3 and Top 5 Peptide and Oligonucleotide CDMO Companies in Global Market, by Revenue in 2022
3.5 Global Companies Peptide and Oligonucleotide CDMO Product Type
3.6 Tier 1, Tier 2 and Tier 3 Peptide and Oligonucleotide CDMO Players in Global Market
3.6.1 List of Global Tier 1 Peptide and Oligonucleotide CDMO Companies
3.6.2 List of Global Tier 2 and Tier 3 Peptide and Oligonucleotide CDMO Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Peptide and Oligonucleotide CDMO Market Size Markets, 2022 & 2029
4.1.2 Peptide CDMO
4.1.3 Oligonucleotide CDMO
4.2 By Type – Global Peptide and Oligonucleotide CDMO Revenue & Forecasts
4.2.1 By Type – Global Peptide and Oligonucleotide CDMO Revenue, 2018-2023
4.2.2 By Type – Global Peptide and Oligonucleotide CDMO Revenue, 2024-2029
4.2.3 By Type – Global Peptide and Oligonucleotide CDMO Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Peptide and Oligonucleotide CDMO Market Size, 2022 & 2029
5.1.2 Pharmaceutical and Biotechnology Companies
5.1.3 Research Institutes
5.1.4 Others
5.2 By Application – Global Peptide and Oligonucleotide CDMO Revenue & Forecasts
5.2.1 By Application – Global Peptide and Oligonucleotide CDMO Revenue, 2018-2023
5.2.2 By Application – Global Peptide and Oligonucleotide CDMO Revenue, 2024-2029
5.2.3 By Application – Global Peptide and Oligonucleotide CDMO Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Peptide and Oligonucleotide CDMO Market Size, 2022 & 2029
6.2 By Region – Global Peptide and Oligonucleotide CDMO Revenue & Forecasts
6.2.1 By Region – Global Peptide and Oligonucleotide CDMO Revenue, 2018-2023
6.2.2 By Region – Global Peptide and Oligonucleotide CDMO Revenue, 2024-2029
6.2.3 By Region – Global Peptide and Oligonucleotide CDMO Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Peptide and Oligonucleotide CDMO Revenue, 2018-2029
6.3.2 US Peptide and Oligonucleotide CDMO Market Size, 2018-2029
6.3.3 Canada Peptide and Oligonucleotide CDMO Market Size, 2018-2029
6.3.4 Mexico Peptide and Oligonucleotide CDMO Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Peptide and Oligonucleotide CDMO Revenue, 2018-2029
6.4.2 Germany Peptide and Oligonucleotide CDMO Market Size, 2018-2029
6.4.3 France Peptide and Oligonucleotide CDMO Market Size, 2018-2029
6.4.4 U.K. Peptide and Oligonucleotide CDMO Market Size, 2018-2029
6.4.5 Italy Peptide and Oligonucleotide CDMO Market Size, 2018-2029
6.4.6 Russia Peptide and Oligonucleotide CDMO Market Size, 2018-2029
6.4.7 Nordic Countries Peptide and Oligonucleotide CDMO Market Size, 2018-2029
6.4.8 Benelux Peptide and Oligonucleotide CDMO Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Peptide and Oligonucleotide CDMO Revenue, 2018-2029
6.5.2 China Peptide and Oligonucleotide CDMO Market Size, 2018-2029
6.5.3 Japan Peptide and Oligonucleotide CDMO Market Size, 2018-2029
6.5.4 South Korea Peptide and Oligonucleotide CDMO Market Size, 2018-2029
6.5.5 Southeast Asia Peptide and Oligonucleotide CDMO Market Size, 2018-2029
6.5.6 India Peptide and Oligonucleotide CDMO Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Peptide and Oligonucleotide CDMO Revenue, 2018-2029
6.6.2 Brazil Peptide and Oligonucleotide CDMO Market Size, 2018-2029
6.6.3 Argentina Peptide and Oligonucleotide CDMO Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Peptide and Oligonucleotide CDMO Revenue, 2018-2029
6.7.2 Turkey Peptide and Oligonucleotide CDMO Market Size, 2018-2029
6.7.3 Israel Peptide and Oligonucleotide CDMO Market Size, 2018-2029
6.7.4 Saudi Arabia Peptide and Oligonucleotide CDMO Market Size, 2018-2029
6.7.5 UAE Peptide and Oligonucleotide CDMO Market Size, 2018-2029
7 Peptide and Oligonucleotide CDMO Companies Profiles
7.1 Lonza Group Ltd.
7.1.1 Lonza Group Ltd. Company Summary
7.1.2 Lonza Group Ltd. Business Overview
7.1.3 Lonza Group Ltd. Peptide and Oligonucleotide CDMO Major Product Offerings
7.1.4 Lonza Group Ltd. Peptide and Oligonucleotide CDMO Revenue in Global Market (2018-2023)
7.1.5 Lonza Group Ltd. Key News & Latest Developments
7.2 Thermo Fisher Scientific Inc.
7.2.1 Thermo Fisher Scientific Inc. Company Summary
7.2.2 Thermo Fisher Scientific Inc. Business Overview
7.2.3 Thermo Fisher Scientific Inc. Peptide and Oligonucleotide CDMO Major Product Offerings
7.2.4 Thermo Fisher Scientific Inc. Peptide and Oligonucleotide CDMO Revenue in Global Market (2018-2023)
7.2.5 Thermo Fisher Scientific Inc. Key News & Latest Developments
7.3 Merck KGaA
7.3.1 Merck KGaA Company Summary
7.3.2 Merck KGaA Business Overview
7.3.3 Merck KGaA Peptide and Oligonucleotide CDMO Major Product Offerings
7.3.4 Merck KGaA Peptide and Oligonucleotide CDMO Revenue in Global Market (2018-2023)
7.3.5 Merck KGaA Key News & Latest Developments
7.4 Catalent, Inc.
7.4.1 Catalent, Inc. Company Summary
7.4.2 Catalent, Inc. Business Overview
7.4.3 Catalent, Inc. Peptide and Oligonucleotide CDMO Major Product Offerings
7.4.4 Catalent, Inc. Peptide and Oligonucleotide CDMO Revenue in Global Market (2018-2023)
7.4.5 Catalent, Inc. Key News & Latest Developments
7.5 Genscript Biotech Corporation
7.5.1 Genscript Biotech Corporation Company Summary
7.5.2 Genscript Biotech Corporation Business Overview
7.5.3 Genscript Biotech Corporation Peptide and Oligonucleotide CDMO Major Product Offerings
7.5.4 Genscript Biotech Corporation Peptide and Oligonucleotide CDMO Revenue in Global Market (2018-2023)
7.5.5 Genscript Biotech Corporation Key News & Latest Developments
7.6 Polypeptide Group
7.6.1 Polypeptide Group Company Summary
7.6.2 Polypeptide Group Business Overview
7.6.3 Polypeptide Group Peptide and Oligonucleotide CDMO Major Product Offerings
7.6.4 Polypeptide Group Peptide and Oligonucleotide CDMO Revenue in Global Market (2018-2023)
7.6.5 Polypeptide Group Key News & Latest Developments
7.7 Bachem Holding AG
7.7.1 Bachem Holding AG Company Summary
7.7.2 Bachem Holding AG Business Overview
7.7.3 Bachem Holding AG Peptide and Oligonucleotide CDMO Major Product Offerings
7.7.4 Bachem Holding AG Peptide and Oligonucleotide CDMO Revenue in Global Market (2018-2023)
7.7.5 Bachem Holding AG Key News & Latest Developments
7.8 Wuxi Apptec Co., Ltd.
7.8.1 Wuxi Apptec Co., Ltd. Company Summary
7.8.2 Wuxi Apptec Co., Ltd. Business Overview
7.8.3 Wuxi Apptec Co., Ltd. Peptide and Oligonucleotide CDMO Major Product Offerings
7.8.4 Wuxi Apptec Co., Ltd. Peptide and Oligonucleotide CDMO Revenue in Global Market (2018-2023)
7.8.5 Wuxi Apptec Co., Ltd. Key News & Latest Developments
7.9 Ajinomoto Co., Inc.
7.9.1 Ajinomoto Co., Inc. Company Summary
7.9.2 Ajinomoto Co., Inc. Business Overview
7.9.3 Ajinomoto Co., Inc. Peptide and Oligonucleotide CDMO Major Product Offerings
7.9.4 Ajinomoto Co., Inc. Peptide and Oligonucleotide CDMO Revenue in Global Market (2018-2023)
7.9.5 Ajinomoto Co., Inc. Key News & Latest Developments
7.10 Rentschler Biopharma SE
7.10.1 Rentschler Biopharma SE Company Summary
7.10.2 Rentschler Biopharma SE Business Overview
7.10.3 Rentschler Biopharma SE Peptide and Oligonucleotide CDMO Major Product Offerings
7.10.4 Rentschler Biopharma SE Peptide and Oligonucleotide CDMO Revenue in Global Market (2018-2023)
7.10.5 Rentschler Biopharma SE Key News & Latest Developments
7.11 Corden Pharma GmbH
7.11.1 Corden Pharma GmbH Company Summary
7.11.2 Corden Pharma GmbH Business Overview
7.11.3 Corden Pharma GmbH Peptide and Oligonucleotide CDMO Major Product Offerings
7.11.4 Corden Pharma GmbH Peptide and Oligonucleotide CDMO Revenue in Global Market (2018-2023)
7.11.5 Corden Pharma GmbH Key News & Latest Developments
7.12 Senn Chemicals AG
7.12.1 Senn Chemicals AG Company Summary
7.12.2 Senn Chemicals AG Business Overview
7.12.3 Senn Chemicals AG Peptide and Oligonucleotide CDMO Major Product Offerings
7.12.4 Senn Chemicals AG Peptide and Oligonucleotide CDMO Revenue in Global Market (2018-2023)
7.12.5 Senn Chemicals AG Key News & Latest Developments
7.13 Almac Group
7.13.1 Almac Group Company Summary
7.13.2 Almac Group Business Overview
7.13.3 Almac Group Peptide and Oligonucleotide CDMO Major Product Offerings
7.13.4 Almac Group Peptide and Oligonucleotide CDMO Revenue in Global Market (2018-2023)
7.13.5 Almac Group Key News & Latest Developments
7.14 Lonza Custom Manufacturing
7.14.1 Lonza Custom Manufacturing Company Summary
7.14.2 Lonza Custom Manufacturing Business Overview
7.14.3 Lonza Custom Manufacturing Peptide and Oligonucleotide CDMO Major Product Offerings
7.14.4 Lonza Custom Manufacturing Peptide and Oligonucleotide CDMO Revenue in Global Market (2018-2023)
7.14.5 Lonza Custom Manufacturing Key News & Latest Developments
7.15 Creative Peptides
7.15.1 Creative Peptides Company Summary
7.15.2 Creative Peptides Business Overview
7.15.3 Creative Peptides Peptide and Oligonucleotide CDMO Major Product Offerings
7.15.4 Creative Peptides Peptide and Oligonucleotide CDMO Revenue in Global Market (2018-2023)
7.15.5 Creative Peptides Key News & Latest Developments
7.16 Swiss Customized Synthesis
7.16.1 Swiss Customized Synthesis Company Summary
7.16.2 Swiss Customized Synthesis Business Overview
7.16.3 Swiss Customized Synthesis Peptide and Oligonucleotide CDMO Major Product Offerings
7.16.4 Swiss Customized Synthesis Peptide and Oligonucleotide CDMO Revenue in Global Market (2018-2023)
7.16.5 Swiss Customized Synthesis Key News & Latest Developments
7.17 Syngene
7.17.1 Syngene Company Summary
7.17.2 Syngene Business Overview
7.17.3 Syngene Peptide and Oligonucleotide CDMO Major Product Offerings
7.17.4 Syngene Peptide and Oligonucleotide CDMO Revenue in Global Market (2018-2023)
7.17.5 Syngene Key News & Latest Developments
7.18 Eurogentec
7.18.1 Eurogentec Company Summary
7.18.2 Eurogentec Business Overview
7.18.3 Eurogentec Peptide and Oligonucleotide CDMO Major Product Offerings
7.18.4 Eurogentec Peptide and Oligonucleotide CDMO Revenue in Global Market (2018-2023)
7.18.5 Eurogentec Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer